The recent call on Nigerian scientists by the Tertiary Education Trust Fund (TETFund) to develop vaccine against Lassa fever has resonated the critical need for scientific discoveries to produce practical solutions to national problems.
 
For decades, Nigeria has recorded seasonal outbreak of the disease. While universities have continued to research on it, no indigenous vaccine has emerged despite the country’s position as the global epicentre of the viral infection.
 
It was against this backdrop that the Executive Secretary of TETFund, Dr. Sonny Echono, challenged researchers to redirect attention towards vaccines development, describing immunisation as the most effective weapon against infectious diseases.
 
He made the call during the presentation of findings from a N250 million TETFund funded Mega Research Project on Lassa fever conducted by the Federal University of Health Sciences, Otukpo (FUHSO), Benue State.
 
Beyond unveiling fresh scientific evidence on the disease, the event highlighted a growing shift in Nigeria’s research funding philosophy, from financing studies for academic advancement to supporting innovations to address national challenges.
 
The intervention also reflects TETFund’s increasing emphasis on impact driven research. Over the years, the Fund has invested billions of naira in research grants across tertiary institutions. However, concerns have persisted over the limited translation of research findings into commercial products, public policies or technologies that directly benefit society. By challenging scientists to pursue a vaccine, Echono signalled that government expects publicly funded research to produce measurable national outcomes.
 
He further asked about  the quickest path to developing a vaccine, how Nigeria can reduce the burden of Lassa fever and what additional supports are expected of TETFund  to make vaccine development a reality.
 
The challenge is particularly significant because Nigeria bears one of the heaviest global burdens of Lassa fever. According to the Principal Investigator, Prof. Joseph Okopi, between 5,000 and 10,000 Nigerians die from the disease yearly, making it one of the country’s deadliest endemic viral infections.
 
However, TETFund sponsored study has provided valuable scientific insights. Described as the largest multi state population surveillance study on Lassa fever ever conducted in the country, it examined antibody prevalence, rodent reservoirs, transmission patterns and environmental risk factors.
 
Result showed that Benue State has the highest prevalence of Lassa fever antibodies among the five states surveyed. The research also identified poor housing conditions, rodent infestation, contaminated food, leaking roofs and poorly fitted doors as major drivers of infection.
 
Contrary to widespread belief, the study found no evidence that merely eating rodents  predicts Lassa fever infection. Rather, environmental conditions that encourage frequent human contact with infected rodents appear to pose a greater risk.
 
The clinical component of the research equally offers important lessons for the health sector. Of the 392 suspected Lassa fever cases investigated in Benue and Kogi States, only 43 were confirmed through polymerase chain reaction testing. The study further established that bleeding and seizure were the strongest predictors of death among infected patients.
 
Beyond the scientific discoveries, the project demonstrated the growing research capacity within  universities. According to FUHSO Vice Chancellor, Prof. Francis A. Uba, the grant enabled the institution to upgrade laboratory facilities, strengthen research infrastructure, train scientists and establish collaborations.
 
The university is currently seeking designation as a National Centre of Excellence in Infectious Diseases Research, a proposal that may gain traction if government decides to build on the momentum generated by the project.
  
However, vaccine development remains one of the most demanding areas of biomedical science. Moving from laboratory findings to a licensed vaccine requires years of additional research, pre-clinical studies, multiple phases of clinical trials, regulatory approvals, manufacturing capacity and sustained financial investment.
 
This reality suggests that TETFund alone cannot shoulder the responsibility but needs to collaborate with universities, Nigeria Centre for Disease Control and Prevention, the Federal Ministry of Health, pharmaceutical companies, international research institutions and development partners.
 
Recognising this, Echono disclosed that the Fund intends to present the research findings to relevant government agencies and that if successfully validated, the findings could also strengthen the case for establishing a dedicated vaccine development centre in the country.
 
The significance of this approach extends beyond Lassa fever. Considering that Nigeria has continued to grapple with several infectious diseases, including cholera, Yellow fever, meningitis and other viral haemorrhagic fevers, building local vaccine research and production capacity will reduce dependence on imported vaccines, improve national health security and better position the country to respond more rapidly to future disease outbreaks.
 
For TETFund, the Lassa fever project may also serve as a benchmark for evaluating the impact of future research grants. Increasingly, research funders around the world are demanding demonstrable outcomes, patents, products, policy influence and commercialisation rather than academic publications alone. Nigeria appears to be moving in the same direction.
 
No doubt, TETFund is repositioning Nigerian universities as centres of innovation, where research is measured not only by publications and conference presentations, but also by its ability to solve national problems. Thus, if the current momentum is sustained through consistent funding, strong partnerships and supportive government policies,  researchers may become key drivers of medical breakthroughs.